Division of Hematology/Oncology

Faculty

faculty photo

Angela M DeMichele, MD MSCE

Alan and Jill Miller Associate Professor in Breast Cancer Excellence
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Co-Leader, Breast Cancer Program, Abramson Cancer Center, University of Pennsylvania
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
3 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-5730
Fax: 215-615-3349
Education:
B.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Post-Graduate Training
Intern in Obstetrics and Gynecology, Hospital of the University of Pennsylvania, 1991-1992.
Resident in Medicine, Hospital of the University of Pennsylvania, 1992-1994.
Visiting Clinical Fellow, Istituto di Ematologia Seràgnoli, Institute of Hematology, Università degli Studi di Bologna, 1994-1995.
Fellowship, Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, 1995-1998.
Certifications
National Board of Medical Examiners, 1992.
American Board of Internal Medicine (Medicine), 1995.
American Board of Internal Medicine (Onc Subspecialty), 1998.
American College of Epidemiology , 2002.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology

Description of Clinical Expertise

breast cancer, neoadjuvant therapy, menopausal symptoms related to cancer, cancer survivorship

Selected Publications

Tan AS, Nagler RH, Hornik RC, DeMichele A: Evolving information needs among colon, breast, and prostate cancer survivors: results from a longitudinal mixed- effects analysis. Cancer Epidemiol Biomarkers Prev 24: 1071-8, July 2015.

Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ: Association between self-report adherence measures and oestrogen supression among breast cancer survivors on aromatase inhibitors. European Journal of Cancer Epub ahead of print, July 2015.

DeMichele A, Chodosh LA: "Braking" the cycle of resistance in endocrine therapy for breast cancer. Clinical Cancer Research Epub ahead of print, July 2015.

Ashraf A, Gaonkar B, Mies C, DeMichele A, Rosen M, Davatzikos C, Kontos D: Breast DCE-MRI kinetic heterogeneity tumor markers: Preliminary associates with neoadjuvant chemotherapy response. Translational Oncology June 2015.

Bauml J, Chen L, Chen J, Boyer J, Kalos M, Li SQ, DeMichele A, Mao JJ: Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with comorbid fatigue and insomnia? Breast Cancer Research 17: 89, June 2015.

Chung SH, Feldman MD, Martinez D, Kim H, Putt ME, Busch DR, Tchou J, Czerniecki BJ, Schnall MD, Rosen MA, DeMichele A, Yodh AG, Choe R: Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures. Breast Cancer Research 17: 72, May 2015.

Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ: Anti- HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2- positive breast cancer. Breast Cancer Research 17: 71, May 2015.

DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P: CDK4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety and Predictive Biomarker Assessment. Clinical Cancer Research 21(5): 995-1001, March 2015.

Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C.: Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small cell lung cancer, non small cell lung cancer, head and neck squamous carcinoma and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncology Epub ahead of print, February 2015.

White J, DeMichele A: Neoadjuvant therapy for breast cancer: controversies in clinical trial design and standard of care. American Society of Clinical Oncology Education Book 35: 17-23, 2015.

back to top
Last updated: 07/29/2015
The Trustees of the University of Pennsylvania
 

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter